Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10828242 | 0.81 | PDK2 (0.44) | KMT2APDK2PDK4PGRDAO | |
| SCHEMBL30403360 | 0.80 | KMT2A (0.47) | KMT2ACHEK1NPC1KDM4EMEN1 | |
| SCHEMBL24189179 | 0.80 | KMT2A (0.47) | KMT2ACHEK1NPC1KDM4EMEN1 | |
| SCHEMBL3484217 | 0.79 | KMT2A (0.46) | KMT2APGRCHEK1NPC1KDM4E | |
| SCHEMBL6583214 | 0.77 | PDK2 (0.41) | KMT2APDK2PDK4PGRNPC1 | |
| SCHEMBL8555625 | 0.76 | CYP3A4 (0.43) | KMT2APDK2PDK4KDM4EMEN1 | |
| SCHEMBL3158942 | 0.75 | PDK2 (0.36) | KMT2APDK2PDK4PGRCHEK1 | |
| SCHEMBL2270532 | 0.75 | PDK2 (0.53) | KMT2APDK2PDK4PGRDAO | |
| SCHEMBL24112426 | 0.75 | PDK2 (0.53) | PDK2PDK4PGRDAOHTR6 | |
| SCHEMBL10916257 | 0.74 | PGR (0.48) | KMT2APGRCHEK1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011092293-A2 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| US-7122680-B2 | 3-Substituted oxindole β3 agonsists | ELI LILLY AND COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-7087635-B2 | 3-substituted oxindole β3 agonists | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1341759-B1 | 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1444224-B1 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | LILLY CO ELI (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050159473-A1 | 3-Substituted oxindole beta3 agonists | SALL DANIEL J (US) | 2005-07-21 | — | — | US | disclosed |
| US-6911463-B2 | 3-substituted oxindole β-3 agonists | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050054713-A1 | 3-Substituted oxindole beta3 agonists | JESUDASON CYNTHIA DARSHINI (US) | 2005-03-10 | — | — | US | disclosed |
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | SALL DANIEL JON (US) | 2004-12-02 | — | — | US | disclosed |
| US-6825220-B2 | INVOLVES THE RELATIONSHIP BETWEEN ADRENERGIC RECEPTOR STIMULATION AND ANTI-HYPERGLYCEMIC EFFECTS | ELI LILLY AND COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1444224-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040097532-A1 | 3-Substituted oxindole beta 3 agonists | ELI LILLY AND COMPANY | 2004-05-20 | — | — | US | disclosed |
| WO-2003016276-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0780388-B1 | 5HT1Dalpha and 5HT2A ligands | LILLY CO ELI (GB) | 2001-08-16 | — | — | EP | disclosed |
| US-5773448-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-06-30 | — | — | US | disclosed |
| EP-0780388-A1 | 5HT1Dalpha and 5HT2A ligands | LILLY INDUSTRIES LIMITED (GB) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | ADRB3, ADRB2, ADRB1 | KMT2A 3728/4885PDK2 517/4885PDK4 901/4885 |
| US-20050054713-A1 | 3-Substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRB1 | KMT2A 3741/4885PDK2 2379/4885PDK4 2685/4885 |
| US-20050159473-A1 | 3-Substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRB1 | KMT2A 3891/4885PDK2 734/4885PDK4 1014/4885 |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, CRH | KMT2A 3173/4885PDK2 2556/4885PDK4 2817/4885 |
| US-20040097532-A1 | 3-Substituted oxindole beta 3 agonists | ADRB3, ADRB2, ADRB1 | KMT2A 3844/4885PDK2 2277/4885PDK4 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.